Erythropoietin in patients with acute st-segment elevation myocardial infarction undergoing primary : Percutaneous coronary intervention a randomized, double-blind trial

Circulation: Cardiovascular Interventions

Volumn 3, Issue 5, 2010, Pages 408-413

  Ott, Ilka ^b   Schulz, Stefanie ^a   Mehilli, Julinda ^a   Fichtner, Stefanie ^a   Hadamitzky, Martin ^a   Hoppe, Katharina ^b   Ibrahim, Tareq ^a   Martinoff, Steffan ^a   Massberg, Steffen ^a   Laugwitz, Karl Ludwig ^b   Dirschinger, Josef ^b   Schwaiger, Markus ^b   Kastrati, Adnan ^a   Schömig, Albert ^b  

^a Medizinische Klinik rechts der Isar ^*

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Angioplasty; MRI; Myocardial infarction

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; HEPARIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN;

ACUTE HEART INFARCTION; ADULT; ARTICLE; CARDIAC PATIENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPTIC SHOCK; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; STROKE; TRANSLUMINAL CORONARY ANGIOPLASTY;

AGED; ANGIOPLASTY; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; ERYTHROPOIETIN; FOLLOW-UP STUDIES; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; MYOCARDIUM; RECURRENCE; STROKE; STROKE VOLUME; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 78349287458     PISSN: 19417640     EISSN: 19417632     Source Type: Journal    
DOI: 10.1161/CIRCINTERVENTIONS.109.904425     Document Type: Article

References (20)

1. Anagnostou A, Liu Z, Steiner M, Chin K, Lee ES, Kessimian N, Noguchi CT. Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci U S A. 1994;91:3974-3978. (Pubitemid 24139555)
2. Wright GL, Hanlon P, Amin K, Steenbergen C, Murphy E, Arcasoy MO. Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischemia-reperfusion injury. FASEB J. 2004;18: 1031-1033. (Pubitemid 39561515)
3. Calvillo L, Latini R, Kajstura J, Leri A, Anversa P, Ghezzi P, Salio M, Cerami A, Brines M. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci U S A. 2003;100:4802-4806. (Pubitemid 36457809)
4. Shi Y, Rafiee P, Su J, Pritchard KA Jr, Tweddell JS, Baker JE. Acute cardioprotective effects of erythropoietin in infant rabbits are mediated by activation of protein kinases and potassium channels. Basic Res Cardiol. 2004;99:173-182. (Pubitemid 38594226)
5. Hanlon PR, Fu P, Wright GL, Steenbergen C, Arcasoy MO, Murphy E. Mechanisms of erythropoietin-mediated cardioprotection during ischemia- reperfusion injury: Role of protein kinase C and phosphatidylinositol 3-kinase signaling. FASEB J. 2005;19:1323-1325. (Pubitemid 41113737)
6. Bullard AJ, Govewalla P, Yellon DM. Erythropoietin protects the myocardium against reperfusion injury in vitro and in vivo. Basic Res Cardiol. 2005;100:397-403. (Pubitemid 41300494)
7. Tramontano AF, Muniyappa R, Black AD, Blendea MC, Cohen I, Deng L, Sowers JR, Cutaia MV, El-Sherif N. Erythropoietin protects cardiac myocytes from hypoxia-induced apoptosis through an Akt-dependent pathway. Biochem Biophys Res Commun. 2003;308:990-994. (Pubitemid 36976556)
8. van der Meer P, Lipsic E, Henning RH, Boddeus K, van der Velden J, Voors AA, van Veldhuisen DJ, van Gilst WH, Schoemaker RG. Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. J Am Coll Cardiol. 2005;46:125-133. (Pubitemid 40905140)
9. Heeschen C, Aicher A, Lehmann R, Fichtlscherer S, Vasa M, Urbich C, Mildner-Rihm C, Martin H, Zeiher AM, Dimmeler S. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood. 2003;102:1340-1346. (Pubitemid 36988041)
10. Lipsic E, van der Meer P, Voors AA, Westenbrink BD, van den Heuvel AF, de Boer HC, van Zonneveld AJ, Schoemaker RG, van Gilst WH, Zijlstra F, van Veldhuisen DJ. A single bolus of a long-acting erythropoietin analogue darbepoetin alfa in patients with acute myocardial infarction: A randomized feasibility and safety study. Cardiovasc Drugs Ther. 2006;20:135-141. (Pubitemid 43876097)
11. Ehrenreich H, Hasselblat M, Dembowski C, Cepek L, Lewczuk P, Stiefel S, Rustenbeck H, Breiter N, Jacob S, Knerlich F, Bohn M, Poser W, Rüther E, Kochen M, Gefeller O, Gleiter C, Wessel T, De Ryck M, Itri LM, Prange H, Cerami A, Brines M, Siren A. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med. 2002;8:495-505. (Pubitemid 36337492)
12. Sheehan FH, Mathey DG, Schofer J, Dodge HT, Bolson EL. Factors that determine recovery of left ventricular function after thrombolysis in patients with acute myocardial infarction. Circulation. 1985;71: 1121-1128. (Pubitemid 15036358)
13. Ribatti D, Presta M, Vacca A. Erythropoietin and VEGF exhibit equal angiogenic potential. Microvasc Res. 2002;64:326-333.
14. Kristensen J, Maeng M, Rehling M, Berg JS, Mortensen UM, Nielsen SS, Nielsen TT. Lack of acute cardioprotective effect from preischaemic erythropoietin administration in a porcine coronary occlusion model. Clin Physiol Funct Imaging. 2005;25:305-310. (Pubitemid 41223535)
15. Namiuchi S, Kagaya Y, Ohta J, Shiba N, Sugi M, Oikawa M, Kunii H, Yamao H, Komatsu N, Yui M, Tada H, Sakuma M, Watanabe J, Ichihara T, Shirato K. High serum erythropoietin level is associated with smaller infarct size in patients with acute myocardial infarction who undergo successful primary percutaneous coronary intervention. J Am Coll Cardiol. 2005;45:1406-1412. (Pubitemid 40615610)
16. Silverberg DS, Wexler D, Iaina A. The role of anemia in the progression of congestive heart failure. Is there a place for erythropoietin and intravenous iron? J Nephrol. 2004;17:749-761. (Pubitemid 41158293)
17. Li Y, Takemura G, Okada H, Miyata S, Maruyama R, Li L, Higuchi M, Minatoguchi S, Fujiwara T, Fujiwara H. Reduction of inflammatory cytokine expression and oxidative damage by erythropoietin in chronic heart failure. Cardiovasc Res. 2006;71:684-694. (Pubitemid 44848006)
18. Bennett CL, Silver SM, Djulbegovic B, Samaras AT, Blau CA, Gleason KJ, Barnato SE, Elverman KM, Courtney DM, McKoy JM, Edwards BJ, Tigue CC, Raisch DW, Yarnold PR, Dorr DA, Kuzel TM, Tallman MS, Trifilio SM, West DP, Lai SY, Henke M. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA. 2008;299:914-924. (Pubitemid 351397066)
19. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin: Results of a combined phase I and II clinical trial. N Engl J Med. 1987;316:73-78. (Pubitemid 17052741)
20. Ndrepepa G, Mehilli J, Martinoff S, Schwaiger M, Schomig A, Kastrati A. Evolution of left ventricular ejection fraction and its relationship to infarct size after acute myocardial infarction. J Am Coll Cardiol. 2007;50:149-156. (Pubitemid 47002186)